Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Actavis Inc    

ACTAVIS INC
Mes dernières consult.
Most popular
  Report  
SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Latest news on ACTAVIS INC
2017ALLERGAN : and Richter Announce Positive Topline Results from Phase 3 Study of C..
AQ
2017ALLERGAN : Acknowledges Appeals Court Decision for COMBIGAN
AQ
2017ALLERGAN : to Present at the 36th Annual J.P. Morgan Healthcare Conference
PR
2017ALLERGAN : Acknowledges Appeals Court Decision for COMBIGAN®
PR
2017ALLERGAN : Succession doubts cloud Apotex future after billionaire owner's death
RE
2017ALLERGAN : Succession doubts cloud Apotex future after billionaire owner's death
RE
2017ALLERGAN : VISTABEL Receives Positive Opinion from ANSM for Treatment of Moderat..
AQ
2017ALLERGAN : FDA Accepts NDA For Acne Drug Seysara
AQ
2017ALLERGAN : Receives FDA Clearance For the CoolSculpting® Treatment To Improve Ap..
AQ
2017ALLERGAN : Announces Promotion of Wayne Swanton to Executive Vice President, Glo..
AQ
2017ALLERGAN : and Richter Announce Positive Topline Results from Phase 3 Study of C..
AQ
2017ALLERGAN : VISTABEL® (botulinum toxin type A) Receives Positive Opinion from ANS..
PU
2017ALLERGAN PLC (NYSE : AGN) Files An 8-K Departure of Directors or Certain Officer..
AQ
2017ALLERGAN PLC : Change in Directors or Principal Officers (form 8-K)
AQ
2017TEVA PHARMACEUTICAL INDUSTRIES : Union says workers at Israeli drugs firm Teva t..
RE
2017TEVA PHARMACEUTICAL INDUSTRIES : Union says workers at Israeli drugs firm Teva t..
RE
2017ALLERGAN : and Richter Announce Positive Topline Results from Phase 3 Study of C..
PR
2017ALLERGAN : Announces Promotion of Wayne Swanton to Executive Vice President, Glo..
PR
2017TEVA PHARMACEUTICAL INDUSTRIES : Strike over Teva Pharm job cuts briefly shuts d..
RE
2017ALLERGAN : Receives FDA Clearance for the CoolSculpting Treatment to Improve App..
AQ
2017TEVA PHARMACEUTICAL INDUSTRIES : Fears of Israeli job cuts at Teva sparks call f..
RE
2017ALLERGAN : Receives FDA Clearance For the CoolSculpting® Treatment To Improve Ap..
PU
2017TEVA CONSIDERING CUTTING UP TO 10,00 : Bloomberg
RE
2017TEVA CONSIDERING CUTTING UP TO 10,00 : Bloomberg
RE
2017ALLERGAN : Migraine Leadership Recognized with Enrico Greppi Award for Excellenc..
AQ
2017EDITAS MEDICINE : BioCentury - Editas raises $50M follow-on
AQ
2017Tech firms tell patent court to ignore Allergan deal with tribe
RE
2017ALLERGAN : to Present at the 2017 Citi Global Healthcare Conference
AQ
2017ALLERGAN : Health Care Up on Rotation Out of Tech -- Health Care Roundup
DJ
2017ALLERGAN : Migraine Leadership Recognized with Enrico Greppi Award for Excellenc..
PR
2017ALLERGAN : to Present at the 2017 Citi Global Healthcare Conference
AQ
2017ALLERGAN : to Present at the 2017 Citi Global Healthcare Conference
PR
2017ALLERGAN : to Present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conf..
AQ
2017ALLERGAN : Receives FDA Approval For Use of VRAYLAR cariprazine in the Maintenan..
AQ
2017ALLERGAN PLC : . (AGN) Shares Bought by Bank Hapoalim BM
AQ
2017ALLERGAN : to Present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conf..
PR
2017ALLERGAN : Overactive Bladder Causes Significant Burden Regardless of Age Amongs..
AQ
2017ALLERGAN PLC : Ex-dividend day for
FA
2017ALLERGAN : Receives FDA Approval for Use of VRAYLAR in the Maintenance Treatment..
AQ
2017ALLERGAN : Overactive Bladder Causes Significant Burden, Regardless of Age Among..
PR
2017ALLERGAN : lands FDA approval for schizophrenia drug
AQ
2017ALLERGAN : to sell a quarter of its Teva stake in first quarter 2018
RE
2017Pfizer creates chief operating officer role for Bourla
RE
2017ALLERGAN : Receives FDA Approval For Use of VRAYLAR™ (cariprazine) in the ..
PU
2017Novartis posts eye drug data amid play for Eylea's turf
RE
2017AMGEN : And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevac..
PR
2017ALLERGAN : Receives Approval for Ozurdex® Dexamethasone Intravitreal Implant 0.7..
AQ
2017ALLERGAN : Presented New Phase 3 Data of Ulipristal Acetate in Women with Uterin..
AQ
2017ALLERGAN : UroGen Pharma Announces First Patient Enrolled in Allergan Phase 2 Cl..
AQ
2017SEN. HASSAN AND COLLEAGUES TO ALLERG : Monopoly Keeps Price of Drug High, Limits..
AQ
2017SENATORS TO ALLERGAN CEO : Monopoly Keeps Price of Drug High, Limits Competition
AQ
2017ALLERGAN : to Present Dynamic Eye Care Data at American Academy of Ophthalmology..
PU
2017ALLERGAN : and Regeneron Stumble
AQ
2017ALLERGAN : UroGen Pharma Announces First Patient Enrolled in Allergan Phase 2 Cl..
AQ
2017ALLERGAN : to Present at Credit Suisse 26th Annual Healthcare Conference
PR
2017ALLERGAN : Sen. Margaret Wood Hassan (D-NH) News Release
AQ
2017ALLERGAN : Senators Demand Answers Ahead of House Subcommittee Hearing in Respon..
AQ
2017LEN BLAVATNIK : Billionaire Blavatnik weighs big share purchase in Teva Pharm - ..
RE
2017ALLERGAN : Presented New Phase 3 Data of Ulipristal Acetate in Women
AQ
2017ALLERGAN : Reports Solid Top Line Execution in Third Quarter 2017 with 11% Incre..
AQ
2017ALLERGAN : Board of Directors Announces Fourth Quarter 2017 Cash Dividend and In..
AQ
2017ALLERGAN : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESUL..
AQ
2017ALLERGAN : to begin selling its 10 percent stake in Teva
RE
2017ALLERGAN PLC. (NYSE : AGN) reported earnings of $4.15 per share beating Walls St..
AQ
2017ALLERGAN : reports 3Q loss on charges, but tops expectations
AQ
2017ALLERGAN PLC : Results of Operations and Financial Condition, Financial Statemen..
AQ
2017ALLERGAN : Reports Solid Top-Line Execution in Third Quarter 2017 with 11% Incre..
PR
2017ALLERGAN PLC : to Host Earnings Call
AC
2017ALLERGAN : Presented New Phase 3 Data of Ulipristal Acetate in Women with Uterin..
PU
2017ALLERGAN : Receives Approval for Ozurdex® (Dexamethasone Intravitreal Implant 0...
PR
2017ALLERGAN : Board of Directors Announces Fourth Quarter 2017 Cash Dividend and In..
PR
2017ALLERGAN : to Present New Data at the World Congress of Gastroenterology at ACG ..
AQ
2017COOLSCULPTING : ® Breaks the Ice about Non-Invasive Fat Freezing with Actress De..
PR
2017ALLERGAN : to Present Latest Studies of Ulipristal Acetate for Uterine Fibroids ..
AQ
2017ALLERGAN : to Present Latest Studies of Ulipristal Acetate for Uterine Fibroids ..
PU
Prev.1   2  3  4  5  6  7  8  9  10Next
Financials ($)
Sales 2018 15 196 M
EBIT 2018 7 274 M
Net income 2018 -1 246 M
Debt 2018 22 990 M
Yield 2018 1,83%
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 5,00x
EV / Sales 2019 4,66x
Capitalization 53 014 M
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 216 $
Spread / Average Target 35%
EPS Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Matthew M. Walsh Chief Financial Officer & Executive VP
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
James H. Bloem Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ACTAVIS INC53 014
JOHNSON & JOHNSON-6.33%349 006
NOVARTIS-2.67%224 221
PFIZER-0.58%213 155
ROCHE HOLDING LTD.-9.33%206 183
MERCK AND COMPANY-2.29%148 618